[
    [
        {
            "time": "2021-05-10",
            "original_text": "复星医药（600196）事件点评：拟与BioNTech投资设立合资公司，长期看好mRNA新冠疫苗市场前景！【东吴医药朱国广团队】",
            "features": {
                "keywords": [
                    "复星医药",
                    "BioNTech",
                    "合资",
                    "mRNA",
                    "新冠疫苗"
                ],
                "sentiment_score": 0.9,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": "neutral"
            },
            "scores": {
                "News_content": "复星医药（600196）事件点评：拟与BioNTech投资设立合资公司，长期看好mRNA新冠疫苗市场前景！【东吴医药朱国广团队】",
                "Correlation": 10,
                "Sentiment": 8,
                "Importance": 9,
                "Impact": 8,
                "Duration": 8,
                "Entity_Density": 10,
                "Market_Scope": 6,
                "Time_Proximity": 7,
                "Headline_Structure": 9,
                "Source_Recency": 8
            }
        },
        {
            "time": "2021-05-10",
            "original_text": "多重利好传来：复星医药创历史新高 疫苗板块卷土重来？",
            "features": {
                "keywords": [
                    "复星医药",
                    "历史新高",
                    "疫苗板块"
                ],
                "sentiment_score": 0.85,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "多重利好传来：复星医药创历史新高 疫苗板块卷土重来？",
                "Correlation": 9,
                "Sentiment": 8,
                "Importance": 7,
                "Impact": 7,
                "Duration": 6,
                "Entity_Density": 8,
                "Market_Scope": 8,
                "Time_Proximity": 7,
                "Headline_Structure": 9,
                "Source_Recency": 7
            }
        },
        {
            "time": "2021-05-10",
            "original_text": "瑞信：重申复星医药“跑赢大市”评级 目标价上调15.4%至60港元",
            "features": {
                "keywords": [
                    "瑞信",
                    "复星医药",
                    "跑赢大市",
                    "目标价"
                ],
                "sentiment_score": 0.8,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": "neutral"
            },
            "scores": {
                "News_content": "瑞信：重申复星医药“跑赢大市”评级 目标价上调15.4%至60港元",
                "Correlation": 9,
                "Sentiment": 8,
                "Importance": 8,
                "Impact": 7,
                "Duration": 6,
                "Entity_Density": 9,
                "Market_Scope": 5,
                "Time_Proximity": 8,
                "Headline_Structure": 8,
                "Source_Recency": 8
            }
        },
        {
            "time": "2021-05-10",
            "original_text": "港股复星医药涨幅扩大至25%",
            "features": {
                "keywords": [
                    "港股",
                    "复星医药",
                    "涨幅",
                    "25%"
                ],
                "sentiment_score": 0.75,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "false",
                "causal_impact": "neutral",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "港股复星医药涨幅扩大至25%",
                "Correlation": 10,
                "Sentiment": 9,
                "Importance": 9,
                "Impact": 10,
                "Duration": 5,
                "Entity_Density": 10,
                "Market_Scope": 4,
                "Time_Proximity": 10,
                "Headline_Structure": 8,
                "Source_Recency": 10
            }
        },
        {
            "time": "2021-05-10",
            "original_text": "复星医药拟与BioNTech合资本地化生产mRNA新冠疫苗，年产能将达10亿剂",
            "features": {
                "keywords": [
                    "复星医药",
                    "BioNTech",
                    "合资",
                    "本地化",
                    "mRNA",
                    "新冠疫苗"
                ],
                "sentiment_score": 0.9,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": "neutral"
            },
            "scores": {
                "News_content": "复星医药拟与BioNTech合资本地化生产mRNA新冠疫苗，年产能将达10亿剂",
                "Correlation": 10,
                "Sentiment": 9,
                "Importance": 10,
                "Impact": 9,
                "Duration": 9,
                "Entity_Density": 10,
                "Market_Scope": 7,
                "Time_Proximity": 8,
                "Headline_Structure": 8,
                "Source_Recency": 9
            }
        }
    ]
]